EUVIMEDOpdag EUVIMED
Open access

Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors

Ibrahim M Asiri, Ronald C Chen, Viraj Master, Lanyu Mi, Sarah E James, Alan H Bryce, Umar Afzal, Irbaz B Riaz, Syed Arsalan Ahmed Naqvi, Steven R H Beach, Ewan K Cobran iD

The Prostate · 2025

DOI: 10.1002/pros.24902 ↗

At a glance

Journal article in The Prostate, 2025. Written by Ibrahim M Asiri and 10 co-authors. Institution: Saudi Food & Drug Authority, Riyadh, Saudi Arabia. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant, Cardiovascular Diseases, Androgen Receptor Antagonists, Thromboembolism. Cited 1 times so far (Crossref); 44 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, This work was supported by National Cancer Institute Grant 1K01CA230193 and National Center for Advancing Translational Sciences UL1 Diversity Supplement Grant…, NCATS NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

This study investigates the association between thromboembolic events (TE) and castration‐resistant prostate cancer (CRPC) patients receiving oral androgen receptor pathway inhibitors (ARPi) compared to those undergoing chemotherapy, both with and without a pre‐existing history of cardiovascular disease (CVD).

Methods

A total of 2779 men diagnosed with CRPC were identified using the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016. Patients were stratified based on their CVD history. Within each CVD stratum (pre‐existing CVD vs. no pre‐existing CVD), patients were further categorized into two treatment groups: those receiving oral ARPi and those undergoing chemotherapy. Unadjusted and inverse probability treatment weight (IPTW)‐adjusted proportional hazards models, using Fine and Gray's method, were applied to evaluate the potential association between ARPi treatment and TE.

Results

Patients with pre‐existing CVD treated with ARPi exhibited a significantly lower crude hazard ratio (HR) for TE compared to chemotherapy (HR 0.39, 95% CI 0.27–0.58, p < 0.001). However, after adjustment using IPTW, this association was no longer significant (adjusted hazard ratio [AHR] 1.00, 95% CI 0.75–1.32, p = 0.99). For patients without CVD, ARPi use was also associated with a reduced risk of TE in the crude analysis (HR 0.53, 95% CI 0.32–0.87, p = 0.01), but this effect was not statistically significant after IPTW adjustment (HR 0.99, 95% CI 0.69–1.41, p = 0.94).

Conclusion

ARPi demonstrated no significant effect on TE risk compared to chemotherapy, regardless of pre‐existing CVD status. Similarly, when excluding patients with a prior history of TE, ARPi use remained non‐significantly associated with new TE in the IPTW‐adjusted competing risk analysis, highlighting the need for further investigation.

Subjects

MeSH terms (MEDLINE)

Prostatic Neoplasms, Castration-ResistantCardiovascular DiseasesAndrogen Receptor AntagonistsThromboembolismHumansMaleAgedAged, 80 and overSEER ProgramUnited StatesComorbidityAdministration, Oral

Author keywords

cardiovascular diseasecastration‐resistant prostate cancerchemotherapyoral androgen receptor pathway inhibitorssurveillance epidemiology and end results medicarethromboembolic events

Substances

Androgen Receptor Antagonists

Authors and institutions

  • Saudi Food & Drug Authority, Riyadh, Saudi Arabia.
  • Department of Quantitative Health Science, Mayo Clinic College of Medicine and Sciences, Scottsdale, Arizona, USA.
  • Department of Radiation Oncology, University of Kansas, School of Medicine, Kansas City, Missouri, USA.
  • Department of Urology, School of Medicine, Emory University, Atlanta, Georgia, USA.
  • Department of Radiation Oncology, Mayo Clinic College of Medicine and Sciences, Phoenix, Arizona, USA.
  • City of Hope, Department of Medical Oncology & Therapeutics Research, Phoenix, Arizona, USA.

ORCID profiles: Ewan K Cobran

Funding

  • NCI NIH HHS
  • This work was supported by National Cancer Institute Grant 1K01CA230193 and National Center for Advancing Translational Sciences UL1 Diversity Supplement Grant…
  • NCATS NIH HHS
  • National Cancer Institute

Cite

APA

Asiri, I. M., Chen, R. C., Master, V., Mi, L., James, S. E., Bryce, A. H., Afzal, U., Riaz, I. B., Ahmed Naqvi, S. A., Beach, S. R. H., & Cobran, E. K. (2025). Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors. The Prostate. https://doi.org/10.1002/pros.24902

Vancouver

Asiri IM, Chen RC, Master V, Mi L, James SE, Bryce AH, et al. Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors. The Prostate. 2025. doi:10.1002/pros.24902

BibTeX
@article{Asiri2025,
  author = {Asiri, Ibrahim M and Chen, Ronald C and Master, Viraj and Mi, Lanyu and James, Sarah E and Bryce, Alan H and Afzal, Umar and Riaz, Irbaz B and Ahmed Naqvi, Syed Arsalan and Beach, Steven R H and Cobran, Ewan K},
  title = {Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24902}
}
Start for free →